Sionna Therapeutics, Inc.'s Quiet Period To Expire on March 19th (NASDAQ:SION)

Sionna Therapeutics' (NASDAQ:SION - Get Free Report) quiet period is set to expire on Wednesday, March 19th. Sionna Therapeutics had issued 10,588,233 shares in its initial public offering on February 7th. The total size of the offering was $190,588,194 based on an initial share price of $18.00. During Sionna Therapeutics' quiet period, insiders and underwriters that worked on the IPO are restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Analysts Set New Price Targets

SION has been the subject of several analyst reports. TD Cowen initiated coverage on Sionna Therapeutics in a report on Tuesday, March 4th. They set a "buy" rating for the company. Guggenheim began coverage on shares of Sionna Therapeutics in a research note on Tuesday, March 4th. They set a "buy" rating and a $45.00 price objective for the company. Finally, Stifel Nicolaus initiated coverage on shares of Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a "buy" rating and a $32.00 target price on the stock.

Sionna Therapeutics Stock Performance

SION stock opened at $16.25 on Wednesday. Sionna Therapeutics has a 1 year low of $13.20 and a 1 year high of $25.19.

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads